Ra Pharmaceuticals (Ra Pharmaceuticals) Total Inventories : $0.00 Mil (As of Dec. 2019)

View and export this data going back to 2016. Start your Free Trial

What is Ra Pharmaceuticals Total Inventories?

Ra Pharmaceuticals's total inventories for the quarter that ended in Dec. 2019 was $0.00 Mil. Ra Pharmaceuticals's average total inventories from the quarter that ended in Sep. 2019 to the quarter that ended in Dec. 2019 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Ra Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2019 was $5.14.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Ra Pharmaceuticals Total Inventories Historical Data

The historical data trend for Ra Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ra Pharmaceuticals Total Inventories Chart

Ra Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Total Inventories

Get a 7-Day Free Trial

Ra Pharmaceuticals Quarterly Data
	Dec14	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19
Total Inventories	Get a 7-Day Free Trial														-	-	-	-	-

Ra Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Ra Pharmaceuticals (NAS:RARX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Ra Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2019 is

	Net-Net Working Capital Per Share (Q: Dec. 2019 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(264.992	+	0.75 * 0	+	0.5 * 0	-	22.038
-	0	-	0)	/	47.222
=	5.14

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Ra Pharmaceuticals's Days Inventory for the three months ended in Dec. 2019 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2019 )	/	Cost of Goods Sold (Q: Dec. 2019 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Ra Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2019 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2019 )	/	Average Total Inventories (Q: Dec. 2019 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Ra Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2019 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2019 )	/	Revenue (Q: Dec. 2019 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Ra Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Ra Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Ra Pharmaceuticals (Ra Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ra Pharmaceuticals Inc (NAS:RARX) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

87 Cambridge Park Drive, Cambridge, MA, USA, 02140

Website

http://www.rapharma.com

Ra Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It discovers and develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Geographically business of the firm can be seen amplifying in the United States, Europe and even at international level.

Executives

Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Edward T Mathers	director	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Timothy R Pearson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Aoife Brennan	director	200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Douglas A Treco	director, officer: President and CEO	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Rajeev M. Shah	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alexander Cumbo	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Robert Heft	director	87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140
Patrick J Kerins	10 percent owner
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
David Charles Lubner	officer: Executive VP and CFO	C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472